The negative results of CONDOR, EAGLE, and CheckMate-714 trials hinted at the possible limitation of the activity of anti-CTLA-4 for platinum-resistant R/M HNSCC patients. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.